Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Performance Outlook 2026–2030: Revenue to Hit $45.08 Billion at 27.6% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the transthyretin amyloid cardiomyopathy (attr-cm) treatment market from 2026–2035 with trusted insights from The Business Research Company
What long-term size projections exist for the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market covering 2026–2035?
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market has experienced rapid expansion over recent years. This market is projected to expand from $13.29 billion in 2025 to $17.03 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 28.1%. Historically, this growth can be linked to heightened disease recognition among cardiologists, a rise in the diagnosis of rare cardiomyopathies, the introduction of specific pharmacological treatments, the proliferation of specialized cardiac care facilities, and advancements in genetic screening technologies.
The market for transthyretin amyloid cardiomyopathy (attr-cm) treatments is anticipated to experience substantial growth over the coming years. This market is projected to reach $45.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 27.6%. Key drivers for this expansion during the forecast period include the broader application of precision medicine, the increasing creation of next-generation gene-silencing therapies, greater capital deployment into rare disease drug development, improved patient access to sophisticated cardiac diagnostic tools, and a heightened emphasis on treatments that modify the disease’s progression. Notable trends anticipated for this period encompass the wider acceptance of transthyretin stabilizer therapies, the growing utilization of RNAi-based treatment methods, a sharpened focus on timely diagnosis and ongoing disease surveillance, the broadening of personalized treatment plans, and enhanced funding for research into rare cardiac conditions.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
Which Drivers Are Impacting The Competitive Landscape Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The increasing incidence of chronic illnesses is anticipated to drive the expansion of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in the future. These are prolonged health issues that develop gradually and endure for at least a year, frequently demanding ongoing medical attention. The growing occurrence of chronic diseases stems from various factors, including an aging demographic, inactive routines, poor dietary habits, escalating obesity levels, and exposure to environmental contaminants. Transthyretin amyloid cardiomyopathy treatment works by stabilizing transthyretin, diminishing amyloid accumulation, enhancing cardiac performance, and easing symptoms to more effectively handle associated chronic conditions. As an illustration, the Centers for Disease Control and Prevention (CDC), a federal agency based in the US, reported in April 2025 that roughly 194 million U.S. adults, representing 76.4%, indicated they had at least one chronic condition in 2023. The rate was 59.5% for young adults, 78.4% for midlife adults, and 93.0% for older adults. Consequently, the increasing prevalence of chronic diseases is propelling the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
What Leading Segments Are Studied In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
What Trends Are Expected To Impact The Competitive Landscape Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Leading companies within the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are concentrating on developing innovative therapies for ATTR-CM, such as oral prescription medication intended to target and stabilize transthyretin (TTR) proteins or minimize amyloid fibril buildup in the heart. Oral prescription medication refers to drugs prescribed by a healthcare provider that are taken by mouth, typically in forms like tablets, capsules, or liquid solutions. For instance, in November 2024, BridgeBio Pharma Inc., a US-based biotechnology company, secured approval from the U.S. Food and Drug Administration for Attruby (acoramidis) for managing transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. This intervention stabilizes the TTR protein, leading to a reduction in heart-related deaths and hospitalizations. Clinical trials have indicated that it is well-tolerated and offers rapid benefits by addressing the disease’s underlying cause.
Which Key Market Players Are Investing In Expansion And Innovation Within The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Major companies operating in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market are Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Intellia Therapeutics Inc, SOM Biotech S L, Ionis Pharmaceuticals Inc, Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, Akcea Therapeutics Inc
Access The Complete Report For Deeper Market Insights:
Which Region Is Expected To Experience The Fastest Growth In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp
Browse Through More Reports Similar to the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market 2026, By The Business Research Company
Cardiometabolic Diseases Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
Hypertrophic Cardiomyopathy Treatment Market Report 2026
Hypertrophic Cardiomyopathy Hcm Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
